Shire sees Baxalta deal proceeding despite US tax rules
Pharmaceuticals firm Shire said it expected its $32bn (£22.6bn) merger with Baxalta to go ahead despite new US tax rules stopping the $160bn deal between Pfizer and Allergan.
Allergan Inc.
$240.22
11:00 06/04/15
BAXALTA
861.05
00:00 24/05/16
Dow Jones I.A.
42,125.85
04:30 15/10/20
FTSE 100
8,276.87
15:10 24/09/24
FTSE 350
4,565.13
15:10 24/09/24
FTSE All-Share
4,521.24
15:10 24/09/24
Pfizer Inc.
$29.47
05:10 24/09/24
Pharmaceuticals & Biotechnology
22,061.31
15:10 24/09/24
Shire Plc
4,690.00p
16:39 08/01/19
In a statement, Shire said it expected the Baxalta transaction would proceed as originally announced on January 11, 2016.
“The combination of Shire and Baxalta is based on a strong strategic rationale to create the leading global biotechnology company focused on rare diseases,” Shire said.
“The company currently expects to complete its proposed combination by mid-2016 as previously announced.”
The US Treasury has stopped US firms adopting a foreign address for tax reasons through an acquisition.